Goldman Sachs Upgrades Quest Diagnostics (DGX) to Neutral

Article Stock Quotes (1) Comments (0)

Goldman Sachs upgraded Quest Diagnostics (NYSE: DGX) from Sell to Neutral with a price target of $59.00 (from $55.00).

The firm said they now have greater appreciation for upside to earnings through cost rationalization and additional share repurchase. They also said the defensive sales mix is attractive.

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $59.90 yesterday, with a 52 week range of $45.13-$62.32.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Quest Diagnostics, Inc. (DGX) Declares $0.30 Quarterly Dividend; 2% Yield
• Macquarie Upgrades IntercontinentalExchange (ICE) to Outperform
• Quest Diagnostics Declares Quarterly Cash Dividend

Create E-mail Alert Related Categories

Upgrades

Related Entities

Goldman Sachs, Stock Buyback, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?